	0	11 P	. Vo			1002	11009 - CAO. 10
CODM DTG	.JAN B (n	227	008	APPLICATION NO.:	10/821,809	ATTY. DOCKET NO	.: P0453.70116US01
	(3)		Æ/	FILING DATE:	April 8, 2004	CONFIRMATION N	D.: 9063
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT:	Sanghvi et al.		
				GROUP ART UNIT:	1614	EXAMINER:	Phyllis G. Spivack
Sheet	1	of	1	SACSI ART OWN.		2.0	, 5. opivack

	DOCUMENTS	

Examiner's	Cite No.	U.S. Patent Docum	nent	Name of Patentee or Applicant of Cited Document	Date of Publication or Issue	
Initials "		Number	Kind Code		of Cited Document MM-DD-YYYY	
		2007-0099946	A1	Doshan	05-03-2007	
		2007-0265293 A1		Boyd et al.	11-15-2007	
			ļ			
			<u> </u>			

FOREIGN PATENT DOCUMENTS

TORRIGHT ATENT DOCUMENTS							
Examiner's	Cite	Foreign Patent Document			Name of Patentee or Applicant of Cited	Date of Publication of	Translation
Initials	No.	Office/ Country	Number	Kind Code	Document Document	Cited Document MM-DD-YYYY	(Y/N)
	- 1			1			l.

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		Cancer Weekly Plus Newsletter (August 12, 1996)	
		http://opioids.com/opiates.html	
		http://www.medscape.com/viewarticle/506798_5	
		http://www.medscape.com/viewarticle/442893_4	
		YUAN et al., Methylnaltrexone effects on morphine-induced inhibition in isolated guinea-pig and human intestine. Clin Pharm & Therapeut. 1995 Feb;57:138. Abstract PI-11.	
		ZIMMERMAN et al., Discovery of a potent, peripherally selective trans-3,4-dimethyl-4-(3- hydroxyphenyl) piperidine opioid antagonist for the treatment of gastrointestinal motility disorders. J Med Chem. 1994 Jul 22, 37(15):2262-5.	

EXAMINER:	/Phyllis Spivack/	DATE CONSIDERED:	02/25/2008

⁸ EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

^{*}a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[[]NOTE - No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wimpper (IFW) system, are included. See 37 CFR § 19.8 and 12870G183. Copies of all other patents, publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR § 19.8 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR § 19.8, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. § 120.]